Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDVO.L Regulatory News (DVO)

  • There is currently no data for DVO

Trading Update

29 Apr 2021 07:00

RNS Number : 9817W
Devro PLC
29 April 2021
 

Devro plc

 

Trading Update

 

Devro plc ("Devro" or the "Company"), one of the world's leading manufacturers of collagen products for the food industry, issues the following trading update for the period 1 January 2021 to the current date ahead of its Annual General Meeting today.

Current trading

Q1 2021 edible collagen volumes increased 4.6% compared to the prior year driven by continued good underlying momentum and execution of our growth initiatives. Emerging markets were up 15% led by strong growth in China, South East Asia and Latin America. Mature markets were flat on the prior year, an improvement on the trends seen in 2020. Japan and North America both delivered strong growth but this was offset by lower demand in the UK & Ireland which had benefitted from elevated retail volumes in March 2020 as the pandemic took hold.

Financial position

The Group delivered strong cashflows during Q1, ending the quarter with comparable levels of leverage to 2020 year-end, including the dividend payment made in January 2021.

The Group repaid the US$25 million private placement due on the 19 April 2021 using a combination of available cash resources and RCF drawings. Post this repayment the Group maintains significant liquidity but with a lower average cost of borrowing.

The Group's remaining debt facilities consist of a committed ÂŁ105 million Revolving Credit Facility (RCF), which expires in 2023, and US$75 million of private placements expiring April 2024 (US$50 million) and 2026 (US$25 million).

Outlook

We are encouraged by the good volume growth performance in Q1 and, whilst we expect this trend to continue we remain mindful of the uncertainties arising from the ongoing COVID-19 pandemic and likely foreign exchange headwinds. As a result, our expectations for 2021 remain unchanged.

ENDS 

Contacts:

 

Devro plc

Rutger Helbing

Chief Executive Officer

Tel: 020 3865 7637

Rohan Cummings

Chief Financial Officer

Tel: 020 3865 7637

 

FTI Consulting

Richard Mountain

Nick Hasell

Tel: 020 3727 1340

 

Dividend: In the Company's announcement on 2 March 2021 of its results for the year ended 31 December 2020, the Board proposed a final dividend of 6.3p per share (the "2020 Final Dividend") to be paid on 1 October 2021, to those shareholders on the register at 20 August 2021, subject to shareholder approval at the Annual General Meeting in April 2021. The Board has subsequently resolved to recommend the payment of the 2020 Final Dividend be brought forward from 1 October 2021 to 20 July 2021, to those shareholders on the register at 11 June 2021.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSEFFWAEFSEDL
Date   Source Headline
6th Oct 20157:00 amRNSCompletion of acquisition
6th Aug 20153:51 pmRNSDirector/PDMR Shareholding
5th Aug 20157:00 amRNSINTERIM RESULTS
27th Jul 20152:53 pmRNSListing Rule 9.6.14(R) Disclosure
10th Jul 20157:00 amRNSAcquisition
9th Jun 201511:43 amRNSHolding(s) in Company
1st Jun 20157:00 amRNSTotal Voting Rights
28th May 20152:44 pmRNSHolding(s) in Company
28th May 20152:41 pmRNSHolding(s) in Company
26th May 20158:16 amRNSBlock Listing Six Monthly Return
7th May 20155:10 pmRNSDirector/PDMR Shareholding
29th Apr 20154:15 pmRNSResult of AGM
29th Apr 20157:00 amRNSTrading Update
27th Mar 20157:00 amRNSChange of Auditor
27th Mar 20157:00 amRNS2014 Annual Report
26th Mar 20154:00 pmRNSDirector/PDMR Shareholding
5th Mar 20153:19 pmRNSDirector/PDMR Shareholding
3rd Mar 20152:34 pmRNSDirector Dealings
3rd Mar 20157:00 amRNSRESULTS FOR THE YEAR ENDED 31 DECEMBER 2014
3rd Dec 20144:19 pmRNSBlock Listing Six Monthly Return
21st Oct 201411:27 amRNSDirector/PDMR Shareholding
21st Oct 20147:00 amRNSInterim Management Statement
6th Oct 20141:39 pmRNSHolding(s) in Company
29th Aug 201411:23 amRNSTotal Voting Rights
7th Aug 20149:04 amRNSHolding(s) in Company
1st Aug 20142:38 pmRNSDirector/PDMR Shareholding
30th Jul 20147:00 amRNS2014 Interim Results
19th Jun 201410:03 amRNSHolding(s) in Company
10th Jun 20145:00 pmRNSDirector/PDMR Shareholding
30th May 201411:18 amRNSHolding(s) in Company
30th May 20147:00 amRNSTotal Voting Rights
29th May 201410:13 amRNSDirector/PDMR Shareholding
23rd May 20147:00 amRNSBlock Listing Six Monthly Return
16th May 201411:01 amRNSDirector/PDMR Shareholding
15th May 20149:00 amRNSConfirmation of Board Change
13th May 20145:16 pmRNSDirector/PDMR Shareholding
8th May 201411:49 amRNSHolding(s) in Company
7th May 20147:00 amRNSFurther Information on US Private Placement
1st May 20142:12 pmRNSDirector Dealings
30th Apr 20144:48 pmRNSResult of AGM
30th Apr 20148:27 amRNSTotal Voting Rights
30th Apr 20147:01 amRNSAppointment of Chairman
28th Apr 20147:00 amRNSInterim Management Statement
24th Apr 20144:43 pmRNSHolding(s) in Company
27th Mar 20147:00 amRNSAnnual Financial Report
21st Mar 201411:12 amRNSAdditional Listing
17th Mar 20142:54 pmRNSHolding(s) in Company
10th Mar 201410:54 amRNSHolding(s) in Company
10th Mar 201410:26 amRNSHolding(s) in Company
5th Mar 20144:14 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.